Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Further Expands NexoBrid's® Global Outreach through New Distribution Agreement in Taiwan with Holy Stone Healthcare
YAVNE, Israel , Oct. 16, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in the development of innovative therapies to address unmet needs in severe burn and wound management, today announced an agreement with Holy Stone Healthcare,
View HTML
Toggle Summary MediWound Ltd. Announces Pricing of $22 Million Public Offering of Ordinary Shares
YAVNE, Israel , Sept. 19, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) today announced the pricing of an underwritten public offering of 4,400,000 of its ordinary shares at a price to the public of $5.00 per share. All of the ordinary shares are being offered by MediWound .
View HTML
Toggle Summary MediWound Ltd. Announces Public Offering of Ordinary Shares
YAVNE, Israel , Sept. 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that it has commenced an underwritten public offering of its
View HTML
Toggle Summary MediWound's NexoBrid® Wins Best Poster Presentation Award at the 17th European Burns Association Congress
Award-winning Poster Underscores European Consensus on Benefits of NexoBrid YAVNE, Israel , Sept. 11, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management,
View HTML
Toggle Summary MediWound's NexoBrid® Highlighted in 43 Presentations at the 17th European Burns Association Congress
Burn Experts from across Europe will share their NexoBrid Experience in 2 Plenary Sessions; 23 Oral Presentations and 18 Poster Presentations
View HTML
Toggle Summary MediWound Successfully Completes Second Cohort of EscharEx® Phase 2 Study
Company intends to initiate EscharEx U.S. pivotal program in first half of 2018
View HTML
Toggle Summary MediWound Reports Second Quarter 2017 Financial Results
NexoBrid ® sales double in first half of 2017 BARDA upsizes committed funding by additional $32 million , bringing total contract value to up to $132 million of non-dilutive financing Conference call begins today at 8:30 a.m. Eastern time YAVNE, Israel , Aug.
View HTML
Toggle Summary MediWound to Host Second Quarter 2017 Financial Results Conference Call on August 3, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel , July 28, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the six
View HTML
Toggle Summary BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid® Indications
Commits an Additional $32 Million to Support R&D Activities, Brings Total Non-Dilutive Funding to Up to $132 Million
View HTML
Toggle Summary BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound's NexoBrid® Development
YAVNE, Israel , June 23, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that it received from the U.S.
View HTML